[en] The presence of RGD on nanoparticles allows the targeting of β1 integrins at the apical surface of human M cells and the enhancement of an immune response after oral immunization. To check the hypothesis that non-peptidic ligands targeting intestinal M cells or APCs would be more efficient for oral immunization than RGD, novel non-peptidic and peptidic analogs (RGD peptidomimitic (RGDp), LDV derivative (LDVd) and LDV peptidomimetic (LDVp)) as well as mannose were grafted on the PEG chain of PCL–PEG and incorporated in PLGA-based nanoparticles. RGD and RGDp significantly increased the transport of nanoparticles across an in vitro model of human M cells as compared to enterocytes. RGD, LDVp, LDVd and mannose enhanced nanoparticle uptake by macrophages in vitro. The intraduodenal immunization with RGDp-, LDVd- or mannose-labeled nanoparticles elicited a higher production of IgG antibodies than the intramuscular injection of free ovalbumin or intraduodenal administration of either non-targeted or RGD-nanoparticles. Targeted formulations were also able to induce a cellular immune response. In conclusion, the in vitro transport of nanoparticles, uptake by macrophages and the immune response were positively influenced by the presence of ligands at the surface of nanoparticles. These targeted-nanoparticles could thus represent a promising delivery system for oral immunization.
Research Center/Unit :
Center for Education and Research on Macromolecules (CERM)
Disciplines :
Chemistry Materials science & engineering
Author, co-author :
Fievez, Virginie; Université catholique de Louvain (UCL) > Unité de Pharmacie Galénique (Bruxelles) et Laboratoire de Biochimie cellulaire, toxicologique et nutritionnelle (Louvain-la-Neuve)
Plapied, Laurence; Université catholique de Louvain (UCL),Bruxelles > Unité de Pharmacie Galénique
des Rieux, Anne; Université catholique de Louvain (UCL), Bruxelles > Unité de Pharmacie Galénique
Pourcelle, Vincent; Université catholique de Louvain (UCL) > Unité de Chimie Organique et Médicinale
Freichels, Hélène; Université de Liège - ULiège > Department of Chemistry > Center for Education and Research on Macromolecules (CERM)
Wascotte, Valentine; Université catholique de Louvain (UCL), Bruxelles > Unité de Pharamcie Galénique
Vanderhaegen, Marie-Lyse; Université catholique de Louvain (UCL), Bruxelles > Unité de Pharamcie Galénique
Jérôme, Christine ; Université de Liège - ULiège > Department of Chemistry > Center for Education and Research on Macromolecules (CERM)
Vanderplasschen, Alain ; Université de Liège - ULiège > Département des Maladies infectieuses et parasitaires > Immunologie et vaccinologie
Marchand-Brynaert, Jacqueline; Université catholique de Louvain (UCL) > Unité de Chimie Organique et Médicinale
Préat, Véronique; Université catholique de Louvain (UCL), Bruxelles > Unité de Pharmacie Galénique
Language :
English
Title :
Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination
Publication date :
2009
Journal title :
European Journal of Pharmaceutics and Biopharmaceutics
F.R.S.-FNRS - Fonds de la Recherche Scientifique [BE] DGTRE - Région wallonne. Direction générale des Technologies, de la Recherche et de l'Énergie [BE]
Foster N., and Hirst B.H. Exploiting receptor biology for oral vaccination with biodegradable particulates. Adv. Drug Deliv. Rev. 57 3 (2005) 431-450
Galindo-Rodriguez S.A., Allemann E., Fessi H., and Doelker E. Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. Crit. Rev. Ther. Drug Carrier Syst. 22 5 (2005) 419-464
Holmgren J., and Czerkinsky C. Mucosal immunity and vaccines. Nat. Med. 11 Suppl. 4 (2005) S45-S53
Lavelle E.C., and O'Hagan D.T. Delivery systems and adjuvants for oral vaccines. Expert. Opin. Drug Deliv. 3 6 (2006) 747-762
Silin D.S., Lyubomska O.V., Jirathitikal V., and Bourinbaiar A.S. Oral vaccination: where we are?. Expert. Opin. Drug Deliv. 4 4 (2007) 323-340
Peek L.J., Middaugh C.R., and Berkland C. Nanotechnology in vaccine delivery. Adv. Drug Deliv. Rev. 60 8 (2008) 915-928
Lee V.H.L., and Yamamoto A. Penetration and enzymatic barriers to peptide and protein absorption. Adv. Drug Deliv. Rev. 4 2 (1989) 171-207
des Rieux A., Fievez V., Garinot M., Schneider Y.J., and Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 116 1 (2006) 1-27
Gebert A., Rothkotter H.J., and Pabst R. M cells in Peyer's patches of the intestine. Int. Rev. Cytol. 167 (1996) 91-159
Gebert A., Steinmetz I., Fassbender S., and Wendlandt K.H. Antigen transport into Peyer's patches: increased uptake by constant numbers of M cells. Am. J. Pathol. 164 1 (2004) 65-72
Neutra M.R., Sansonetti P.J., and Kraehenbuhl J.P. M Cells and Microbial Pathogens (2003), Raven Press, Berlin pp. 163-178
Garinot M., Fievez V., Pourcelle V., Stoffelbach F., des Rieux A., Plapied L., Theate I., Freichels H., Jerome C., Marchand-Brynaert J., Schneider Y.J., and Preat V. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J. Control. Release 120 3 (2007) 195-204
Gullberg E., Leonard M., Karlsson J., Hopkins A.M., Brayden D., Baird A.W., and Artursson P. Expression of specific markers and particle transport in a new human intestinal M-cell model. Biochem. Biophys. Res. Commun. 279 3 (2000) 808-813
Hersel U., Dahmen C., and Kessler H. RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials 24 24 (2003) 4385-4415
Biltresse S., Attolini M., Dive G., Cordi A., Tucker G.C., and Marchand-Brynaert J. Novel RGD-like molecules based on the tyrosine template: design, synthesis, and biological evaluation on isolated integrins alphaVbeta3/alphaIIbbeta3 and in cellular adhesion tests. Bioorg. Med. Chem. 12 20 (2004) 5379-5393
Biltresse S., Attolini M., and Marchand-Brynaert J. Cell adhesive PET membranes by surface grafting of RGD peptidomimetics. Biomaterials 26 22 (2005) 4576-4587
Heckmann D., Meyer A., Laufer B., Zahn G., Stragies R., and Kessler H. Rational design of highly active and selective ligands for the alpha5beta1 integrin receptor. Chembiochem. 9 9 (2008) 1397-1407
Adams S.P., and Lobb R.R. Inhibitors of integrin alpha ' beta 1 (VLA-4). Ann. Rep. Med. Chem. 34 179-188 (1999)
Lin K., Ateeq H.S., Hsiung S.H., Chong L.T., Zimmerman C.N., Castro A., Lee W.C., Hammond C.E., Kalkunte S., Chen L.L., Pepinsky R.B., Leone D.R., Sprague A.G., Abraham W.M., Gill A., Lobb R.R., and Adams S.P. Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses. J. Med. Chem. 42 5 (1999) 920-934
Momtaz M., Rerat V., Gharbi S., Gerard E., Pourcelle V., and Marchand-Brynaert J. A graftable LDV peptidomimetic: design, synthesis and application to a blood filtration membrane. Bioorg. Med. Chem. Lett. 18 3 (2008) 1084-1090
Apostolopoulos V., Barnes N., Pietersz G.A., and McKenzie I.F. Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses. Vaccine 18 27 (2000) 3174-3184
Engering A.J., Cella M., Fluitsma D., Brockhaus M., Hoefsmit E.C., Lanzavecchia A., and Pieters J. The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells. Eur. J. Immunol. 27 9 (1997) 2417-2425
Engering A.J., Cella M., Fluitsma D.M., Hoefsmit E.C., Lanzavecchia A., and Pieters J. Mannose receptor mediated antigen uptake and presentation in human dendritic cells. Adv. Exp. Med. Biol. 417 (1997) 183-187
Kricheldorf H.R., Jonte J.M., and Berl M. Polylactones. 3. Copolymerization of glycolide with ll-lactide and other lactones. Makromol. Chem. 12 (1985) 25-38
Cao L.W., Wang H., Li J.S., and Zhang H.S. 6-Oxy-(N-succinimidyl acetate)-9-(2'-methoxycarbonyl)fluorescein as a new fluorescent labeling reagent for aliphatic amines in environmental and food samples using high-performance liquid chromatography. J. Chromatogr. A 1063 1-2 (2005) 143-151
Zweers M.L., Engbers G.H., Grijpma D.W., and Feijen J. In vitro degradation of nanoparticles prepared from polymers based on dl-lactide, glycolide and poly(ethylene oxide). J. Control. Release 100 3 (2004) 347-356
Nguyen C.A., Allemann E., Schwach G., Doelker E., and Gurny R. Cell interaction studies of PLA-MePEG nanoparticles. Int. J. Pharm. 254 1 (2003) 69-72
Vangeyte P., and Jerome R. Amphiphilic block copolymers of high-molecular-weight poly(ethylene oxyde) and either epsilon-caprolactone or gamma-methyl-epsilon caprolactone: synthesis and characterization. J. Pharmacol. Exp. Ther. 42 1132-1142 (2004)
Pourcelle V., Freichels H., Stoffelbach F., uzely-Velty R., Jerome C., and Marchand-Brynaert J. Light induced functionalization of PCL-PEG block copolymers for the covalent immobilization of biomolecules. Biomacromolecules (2009) 10.1021/bm900027r
Pourcelle V., Devouge S., Garinot M., Preat V., and Marchand-Brynaert J. PCL-PEG-based nanoparticles grafted with GRGDS peptide: preparation and surface analysis by XPS. Biomacromolecules 8 (2007) 3977-3983
Lemoine D., Deschuyteneer M., Hogge F., and Preat V. Intranasal immunization against influenza virus using polymeric particles. J. Biomater. Sci. Polym. Ed. 10 8 (1999) 805-825
des Rieux A., Fievez V., Theate I., Mast J., Preat V., and Schneider Y.J. An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells. Eur. J. Pharm. Sci. 30 5 (2007) 380-391
Artursson P. Epithelial transport of drugs in cell culture. I: a model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J. Pharm. Sci. 79 6 (1990) 476-482
Salman H.H., Gamazo C., Agueros M., and Irache J.M. Bioadhesive capacity and immunoadjuvant properties of thiamine-coated nanoparticles. Vaccine 25 48 (2007) 8123-8132
Hase K., Ohshima S., Kawano K., Hashimoto N., Matsumoto K., Saito H., and Ohno H. Distinct gene expression profiles characterize cellular phenotypes of follicle-associated epithelium and M cells. DNA Res. 12 2 (2005) 127-137
Lo D., Tynan W., Dickerson J., Mendy J., Chang H.W., Scharf M., Byrne D., Brayden D., Higgins L., Evans C., and O'Mahony D.J. Peptidoglycan recognition protein expression in mouse Peyer's Patch follicle associated epithelium suggests functional specialization. Cell Immunol. 224 1 (2003) 8-16
Salman H.H., Gamazo C., Campanero M.A., and Irache J.M. Salmonella-like bioadhesive nanoparticles. J. Control. Release 106 1-2 (2005) 1-13
Salman H.H., Gamazo C., Campanero M.A., and Irache J.M. Bioadhesive mannosylated nanoparticles for oral drug delivery. J. Nanosci. Nanotechnol. 6 9-10 (2006) 3203-3209
Dalle F., Jouault T., Trinel P.A., Esnault J., Mallet J.M., d'Athis P., Poulain D., and Bonnin A. Beta-1,2- and alpha-1,2-linked oligomannosides mediate adherence of Candida albicans blastospores to human enterocytes in vitro. Infect. Immun. 71 12 (2003) 7061-7068
Wagner S., Lynch N.J., Walter W., Schwaeble W.J., and Loos M. Differential expression of the murine mannose-binding lectins A and C in lymphoid and nonlymphoid organs and tissues. J. Immunol. 170 3 (2003) 1462-1465
Jordens R., Thompson A., Amons R., and Koning F. Human dendritic cells shed a functional, soluble form of the mannose receptor. Int. Immunol. 11 11 (1999) 1775-1780
Borges O., Tavares J., de S.A., Borchard G., Junginger H.E., and Cordeiro-da-Silva A. Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. Eur. J. Pharm. Sci. 32 4-5 (2007) 278-290
McCluskie M.J., Weeratna R.D., and Davis H.L. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution. Mol. Med. 6 10 (2000) 867-877
McCluskie M.J., Weeratna R.D., Krieg A.M., and Davis H.L. CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine 19 7-8 (2000) 950-957
Gutierro I., Hernandez R.M., Igartua M., Gascon A.R., and Pedraz J.L. Influence of dose and immunization route on the serum IgG antibody response to BSA loaded PLGA microspheres. Vaccine 20 17-18 (2002) 2181-2190
Gutierro I., Hernandez R.M., Igartua M., Gascon A.R., and Pedraz J.L. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine 21 1-2 (2002) 67-77
Storni T., Kundig T.M., Senti G., and Johansen P. Immunity in response to particulate antigen-delivery systems. Adv. Drug Deliv. Rev. 57 3 (2005) 333-355
Salman H.H., Gamazo C., de Smidt P.C., Russell-Jones G., and Irache J.M. Evaluation of bioadhesive capacity and immunoadjuvant properties of vitamin B(12)-Gantrez Nanoparticles. Pharm. Res. 25 12 (2008) 2859-2868